Test Price
2,800 AED✅ Home Collection Available
FAM111A Gene Gracile Bone Dysplasia NGS Test in UAE – Molecular Diagnosis by DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Comprehensive telephonic post-test genetic counselling and result interpretation.
- Insurance & Billing: Direct Billing Verification available via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FAM111A NGS test utilizes advanced next-generation sequencing to identify pathogenic variants in the FAM111A gene, definitively diagnosing gracile bone dysplasia. This severe skeletal and dermatological disorder requires precise molecular confirmation to guide clinical management, surveillance, and family counselling. Our methodology ensures complete gene coverage including intronic regions and copy number variations (CNVs).
| Feature | DNA Labs UAE NGS Test | Targeted Single-Gene Analysis |
|---|---|---|
| Diagnostic Precision | Full-gene sequencing with CNV detection (100% coverage of coding and regulatory regions) | Limited to known mutational hotspots; may miss novel or rare variants |
| Methodology | Illumina-based NGS with orthogonal Sanger confirmation of all clinically significant variants | Sanger sequencing only |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
Physician Insight & Safety Protocols
Ms. Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “A definitive molecular diagnosis of gracile bone dysplasia via the FAM111A NGS test is a cornerstone for informed clinical surveillance and family planning. It is essential to integrate these genetic results within a complete multidisciplinary evaluation, including radiological and dermatological assessments. This test empowers families with the knowledge required for anticipatory care in a regulated medical framework.”
Advisory & Safety Measures
⚠️ Do not discontinue any prescribed medications or initiate new treatments based solely on genetic test results without consulting your managing physician. All clinical interventions must be overseen by a qualified healthcare provider.
Exclusion Criteria & Emergency Red Flags
- Known bleeding diathesis or severe anaemia (may contraindicate venipuncture).
- Active systemic infection or febrile illness at the time of sample collection.
- Inability to provide informed consent as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Seek immediate medical attention if: sudden severe bleeding, fainting, or signs of an allergic reaction appear after the blood draw.
Patient FAQ & Clinical Guidance
1. What does the FAM111A genetic test detect and how can it help me?
A: The test detects pathogenic variants in the FAM111A gene, confirming a diagnosis of gracile bone dysplasia. This precise molecular identification enables accurate clinical prognosis, targeted surveillance for dermatological and immunological complications, and informed reproductive decision-making. It also helps distinguish this syndrome from other overlapping skeletal dysplasias, ensuring optimal management.
2. How is the sample collected and what preparation is required?
A: A hospital-grade phlebotomist performs a VIP Mobile Phlebotomy visit using temperature-controlled cold-chain logistics for sample preservation. You must provide a detailed clinical history and a pedigree chart from prior genetic counselling before collection. Our nursing team will review your medical status and confirm eligibility prior to scheduling the home visit.
3. Is this test covered by insurance and how do I verify my plan?
A: Direct billing verification is available via WhatsApp at +971 54 548 8731 for eligible UAE insurance plans. Our team submits the ICD-10-CM code Q78.8 and manages the pre-authorisation request on your behalf. For minors, legal guardian consent is required in full compliance with UAE federal health data regulations.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly operates within the legal frameworks established for genomic medicine and patient data protection in the United Arab Emirates:
- Data Privacy: Complete adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) ensuring all genetic data is securely stored, processed, and transmitted.
- Health Data Governance: Full compliance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing the secure handling of electronic health records.
- Clinical Safety & Consent: All procedures and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing patient safety and informed consent.
Clinical & Logistical Metadata
| Test Name | FAM111A Gene Gracile Bone Dysplasia NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Cold-Chain Transport) |
| Methodology Used | Next-Generation Sequencing (NGS) with Orthogonal Sanger Confirmation |
| ICD-10-CM Code | Q78.8 |
| LOINC Code | 94474-1 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians